mhy 219.

Maprotiline-d3 is intended for use as an internal standard for the quantification of maprotiline by GC- or LC-MS. Maprotiline is a tricyclic antidepressant. It binds to the norepinephrine transporter (NET) and is selective for NET over the serotonin and dopamine transporters. Maprotiline also binds to the serotonin (5-HT) receptor subtype 5-HT2A, as well as histamine H1, muscarinic acetylcholine, α1-adrenergic, and dopamine D2 receptors. In vivo, maprotiline inhibits norepinephrine reuptake in rat brain and peripheral tissues. It reduces isolation-induced aggressive behavior and inhibits electrical foot-shock stimulation-induced belligerence in mice when administered at doses ranging from 3 to 10 mg kg. Maprotiline also reduces aggressive behavior in rhesus monkeys housed in groups. Formulations containing maprotiline have been used in the treatment of depression and anxiety.

Maprotiline inhibits cell proliferation and metastasis with anticancer effects. Maprotiline induces apoptosis in cancer cells by targeting ERK signaling pathway and CRABP1. Maprotiline is a highly selective norepinephrine reuptake blocker with potent antidepressant properties. [1][2].

Maprotiline-d5 Hydrochloride is a deuterated compound of Maprotiline Hydrochloride. Maprotiline Hydrochloride has a CAS number of 10347-81-6. Maprotiline hydrochloride is a bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.

Maprotiline hydrochloride (Psymion) is a bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.